{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:54:50Z","timestamp":1791449690722,"version":"4.3.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41366-026-02154-8","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:06:36Z","timestamp":1782817596000},"page":"2052-2055","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of metabolic dysfunction-associated steatotic liver disease and hepatic fibrosis: a large-scale study from the Middle East"],"prefix":"10.1038","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7909-3603","authenticated-orcid":false,"given":"Elamin","family":"Abdelgadir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8911-866X","authenticated-orcid":false,"given":"Fatheya","family":"Alawadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fauzia","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaaeldin","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"2154_CR1","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","volume":"35","author":"L Miao","year":"2024","unstructured":"Miao L, Targher G, Byrne CD, Cao YY, Zheng MH. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024;35:697\u2013707. https:\/\/doi.org\/10.1016\/j.tem.2024.02.007.","journal-title":"Trends Endocrinol Metab"},{"key":"2154_CR2","doi-asserted-by":"publisher","unstructured":"Lazarus JV, Brennan PN, Mark HE, Alazawi W, Allen AM, Byrne CD, et al. A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis. Lancet Regional Health \u2013 Europe. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101320.","DOI":"10.1016\/j.lanepe.2025.101320"},{"key":"2154_CR3","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"2154_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16389","author":"E Abdelgadir","year":"2025","unstructured":"Abdelgadir E, Rashid F, Bashier A, Zidan M, McGowan B, Alawadi F. Prevalence of overweight and obesity in adults from the Middle East: a large-scale population-based study. Diab Obes Metab. 2025. https:\/\/doi.org\/10.1111\/dom.16389.","journal-title":"Diab Obes Metab"},{"key":"2154_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"JH Lee","year":"2010","unstructured":"Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42:503\u20138. https:\/\/doi.org\/10.1016\/j.dld.2009.08.002.","journal-title":"Dig Liver Dis"},{"key":"2154_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.37349\/eemd.2024.00008","volume":"1","author":"B Xu","year":"2024","unstructured":"Xu B, Li C, Chen M, Zhang Y. Four hepatic steatosis indices in predicting quantitative computed tomography-based metabolic dysfunction-associated fatty liver disease. Explor Endocr Metab Dis. 2024;1:62\u201376.","journal-title":"Explor Endocr Metab Dis"},{"key":"2154_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/srep16494","volume":"5","author":"J Wang","year":"2015","unstructured":"Wang J, Xu C, Xun Y, Lu Z, Shi J, Yu C, et al. ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population. Sci Rep. 2015;5:16494. https:\/\/doi.org\/10.1038\/srep16494.","journal-title":"Sci Rep"},{"key":"2154_CR8","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/flgastro-2021-102064","volume":"13","author":"AJ Archer","year":"2022","unstructured":"Archer AJ, Belfield KJ, Orr JG, Gordon FH, Abeysekera KW. EASL clinical practice guidelines: non-invasive liver tests for evaluation of liver disease severity and prognosis. Frontline Gastroenterol. 2022;13:436\u20139. https:\/\/doi.org\/10.1136\/flgastro-2021-102064.","journal-title":"Frontline Gastroenterol"},{"key":"2154_CR9","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2154_CR10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739\u201352. https:\/\/doi.org\/10.1016\/S2468-1253(20)30077-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2154_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/joim.13069","volume":"288","author":"B Zou","year":"2020","unstructured":"Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016. J Intern Med. 2020;288:139\u201351. https:\/\/doi.org\/10.1111\/joim.13069.","journal-title":"J Intern Med"},{"key":"2154_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101171","volume":"6","author":"J Boeckmans","year":"2024","unstructured":"Boeckmans J, Michel M, Gieswinkel A, Tuscher O, Konstantinides SV, Konig J, et al. Inflammation in liver fibrosis and atrial fibrillation: a prospective population-based proteomic study. JHEP Rep. 2024;6:101171. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101171.","journal-title":"JHEP Rep"},{"key":"2154_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62549-3","volume":"14","author":"D Ouzan","year":"2024","unstructured":"Ouzan D, Penaranda G, Jlaiel M, Joly H, Corneille J. Using the FIB-4, automatically calculated, followed by the ELF test in second line to screen primary care patients for liver disease. Sci Rep. 2024;14:12198. https:\/\/doi.org\/10.1038\/s41598-024-62549-3.","journal-title":"Sci Rep"},{"key":"2154_CR14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jhep.2019.08.019","volume":"71","author":"M Serra-Burriel","year":"2019","unstructured":"Serra-Burriel M, Graupera I, Toran P, Thiele M, Roulot D, Wai-Sun Wong V, et al. Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia. J Hepatol. 2019;71:1141\u201351. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.019.","journal-title":"J Hepatol"},{"key":"2154_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijmedinf.2006.11.005","volume":"77","author":"J Stausberg","year":"2008","unstructured":"Stausberg J, Lehmann N, Kaczmarek D, Stein M. Reliability of diagnoses coding with ICD-10. Int J Med Inf. 2008;77:50\u20137. https:\/\/doi.org\/10.1016\/j.ijmedinf.2006.11.005.","journal-title":"Int J Med Inf"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02154-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02154-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02154-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:31:27Z","timestamp":1791448287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02154-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2154"],"URL":"https:\/\/doi.org\/10.1038\/s41366-026-02154-8","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EA has received an unrestricted research grant from Novo Nordisk, consulting fees from Astra Zeneca, Novo Nordisk, and Boehringer Ingelheim and honoraria for lectures and presentations and support for attending meetings from Lilly, AstraZeneca, Novo Nordisk, Boehringer Ingelheim, Bayer, and Merck. FA has received honoraria for lectures and presentations and support for attending meetings from AstraZeneca, Novo Nordisk, and Boehringer Ingelheim. FR has received honoraria for lectures and presentations from Novo Nordisk, Bayer, and Merck and support for attending meetings from Novo Nordisk and Abbott. AB has received honoraria for lectures and presentations from MSD, Boehringer Ingelheim, Bayer, and Novo Nordisk. JMS has received consulting fees from Akero, Alentis, Alexion, Altimmune, Astra Zeneca, 89Bio, Bionorica, Boehringer Ingelheim, Boston Pharmaceuticals, Gilead Sciences, GSK, HistoIndex, Ipsen, Inventiva Pharma, Madrigal Pharmaceuticals, PRO.MED.CS Praha a.s., and Kr\u00edya Therapeutics; honoraria for lectures and presentations from AbbVie, Boehringer Ingelheim, Gilead Sciences, Ipsen, Lilly, Novo Nordisk, Madrigal Pharmaceuticals; and has stock options in Hepta Bio.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}